uniQure (NASDAQ:QURE) Share Price Passes Below Fifty Day Moving Average on Insider Selling

Shares of uniQure N.V. (NASDAQ:QURE) passed below its 50-day moving average during trading on Monday after an insider sold shares in the company. The stock has a 50-day moving average of $14.29 and traded as low as $13.65. uniQure shares last traded at $13.95, with a volume of 1,978,275 shares trading hands.

Specifically, insider Jeannette Potts sold 4,670 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the completion of the transaction, the insider now directly owns 115,073 shares in the company, valued at approximately $1,742,205.22. This represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Analyst Ratings Changes

A number of analysts have recently commented on QURE shares. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of uniQure in a research note on Thursday, May 29th. Guggenheim reiterated a “buy” rating and issued a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Cantor Fitzgerald raised uniQure to a “strong-buy” rating in a report on Monday, May 19th. Finally, Wells Fargo & Company reduced their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.82.

uniQure Trading Up 1.9%

The firm has a market capitalization of $778.97 million, a PE ratio of -3.24 and a beta of 0.08. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99. The firm has a fifty day moving average of $14.38 and a 200 day moving average of $13.99.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. The company had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million. Equities research analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Institutional Trading of uniQure

A number of hedge funds have recently bought and sold shares of QURE. Avoro Capital Advisors LLC purchased a new stake in uniQure during the fourth quarter valued at about $38,410,000. Vestal Point Capital LP increased its holdings in shares of uniQure by 58.4% in the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after purchasing an additional 1,767,572 shares during the period. RTW Investments LP increased its holdings in uniQure by 8,936.3% in the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after buying an additional 893,625 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in uniQure by 81.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after buying an additional 794,459 shares during the last quarter. Finally, Boxer Capital Management LLC acquired a new position in uniQure in the fourth quarter worth approximately $13,245,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.